-transparent.png){kind=logo}
Sixty-seven previously untreated patients with Hodgkin's disease, pathologic stages I and II, seen during a 7-year period were evaluted with respect to initial staging and treatment, as well as relapse and retreatment results. The initial treatment consisted of radiation therapy (RT) to an involved field (IF) or an extended field (EF) for patients with stages IA and IIA, or RT and, in recent cases, combination chemotherapy [cyclophosphamide, Oncovin, procarbazine, and prednisone (COPP)] for patients with stages IB and IIB. Nineteen of the 67 patients relapsed (28%), including 11 of 56 patients with stages IA and IIA (20%) and 8 of 11 patients with stages IB and IIB (73%). Seventeen of the 19 relapses occurred within 24 months after completion of the initial therapy (89%). The relapse-free survival at 5 years was 75% for the A patients and 25% for the B patients. The actuarial survival of stage IA and stage IIA patients at 5 years was 91%; there was no significant difference between patients treated initially with either IF or EF. The actuarial survival at 5 years for the patients with stages IB and IIB was 88%, as most responded to a second program of induction therapy. No correlation could be found between the pattern of relapse and the initial pathologic stage or the mode of treatment.
U Mintz, and
J B Miller, and
H M Golomb, and
J Kinzie, and
D L Sweet, and
E P Lester, and
D Variakojis, and
N O Roth, and
R R Blough, and
D J Ferguson, and
J E Ultmann
January 1980,
Oncology,
U Mintz, and
J B Miller, and
H M Golomb, and
J Kinzie, and
D L Sweet, and
E P Lester, and
D Variakojis, and
N O Roth, and
R R Blough, and
D J Ferguson, and
J E Ultmann
August 1991,
Connecticut medicine,
U Mintz, and
J B Miller, and
H M Golomb, and
J Kinzie, and
D L Sweet, and
E P Lester, and
D Variakojis, and
N O Roth, and
R R Blough, and
D J Ferguson, and
J E Ultmann
April 1997,
Cancer,
U Mintz, and
J B Miller, and
H M Golomb, and
J Kinzie, and
D L Sweet, and
E P Lester, and
D Variakojis, and
N O Roth, and
R R Blough, and
D J Ferguson, and
J E Ultmann
June 1982,
Southern medical journal,
U Mintz, and
J B Miller, and
H M Golomb, and
J Kinzie, and
D L Sweet, and
E P Lester, and
D Variakojis, and
N O Roth, and
R R Blough, and
D J Ferguson, and
J E Ultmann
June 1988,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
U Mintz, and
J B Miller, and
H M Golomb, and
J Kinzie, and
D L Sweet, and
E P Lester, and
D Variakojis, and
N O Roth, and
R R Blough, and
D J Ferguson, and
J E Ultmann
January 2006,
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
U Mintz, and
J B Miller, and
H M Golomb, and
J Kinzie, and
D L Sweet, and
E P Lester, and
D Variakojis, and
N O Roth, and
R R Blough, and
D J Ferguson, and
J E Ultmann
October 1991,
Cancer,
U Mintz, and
J B Miller, and
H M Golomb, and
J Kinzie, and
D L Sweet, and
E P Lester, and
D Variakojis, and
N O Roth, and
R R Blough, and
D J Ferguson, and
J E Ultmann
January 1975,
The American journal of roentgenology, radium therapy, and nuclear medicine,
U Mintz, and
J B Miller, and
H M Golomb, and
J Kinzie, and
D L Sweet, and
E P Lester, and
D Variakojis, and
N O Roth, and
R R Blough, and
D J Ferguson, and
J E Ultmann
June 1989,
Hematology/oncology clinics of North America,
U Mintz, and
J B Miller, and
H M Golomb, and
J Kinzie, and
D L Sweet, and
E P Lester, and
D Variakojis, and
N O Roth, and
R R Blough, and
D J Ferguson, and
J E Ultmann
May 1988,
Clinical radiology,
